July 1, 2025 06:00 AM EDTUpdated 06:24 AM
R&D

Beck­ley touts pos­i­tive mid-stage psy­che­del­ic da­ta fol­low­ing atai merg­er plans

Max Bayer

Pharma Reporter

Beck­ley Psytech said its in­tranasal treat­ment best­ed a small-dose com­para­tor in a Phase 2b tri­al of pa­tients with treat­ment-re­sis­tant de­pres­sion, notch­ing an­oth­er win for the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ad­vo­cates urge J&J to ‘put every­thing on the ta­ble’ for gene ther­a­py de­spite failed tri­al

Pfiz­er ends Phase 2 tri­al for fi­nal Tril­li­um CD47 drug

Broad In­sti­tute con­ducts lay­offs as it preps for cuts in fed­er­al fund­ing; Dyne’s fi­nanc­ing

Kevin Tang's Con­cen­tra snags an­oth­er buy­out, this time for IGM Bio­sciences

Ex­clu­sive: Bob Langer-found­ed Syn­tis Bio gets $33M Se­ries A for obe­si­ty, rare dis­ease drugs

Un­nat­ur­al Prod­ucts taps ar­genx's help for ringed mol­e­cules, ex­pands in­ter­nal work in­to obe­si­ty

A service from the Financial Times